Annual EBITDA
-$54.11 M
+$10.94 M+16.82%
31 December 2023
Summary:
MoonLake Immunotherapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$54.11 million, with the most recent change of +$10.94 million (+16.82%) on 31 December 2023. MLTX annual EBITDA is now at all-time high.MLTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$43.08 M
-$12.53 M-41.01%
30 September 2024
Summary:
MoonLake Immunotherapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$43.08 million, with the most recent change of -$12.53 million (-41.01%) on 30 September 2024. Over the past year, it has dropped by -$30.11 million (-232.06%). MLTX quarterly EBITDA is now -587.63% below its all-time high of -$6.26 million, reached on 30 September 2021.MLTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$108.45 M
-$30.11 M-38.43%
30 September 2024
Summary:
MoonLake Immunotherapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$108.45 million, with the most recent change of -$30.11 million (-38.43%) on 30 September 2024. Over the past year, it has dropped by -$52.68 million (-94.44%). MLTX TTM EBITDA is now -231.84% below its all-time high of -$32.68 million, reached on 30 June 2021.MLTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MLTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +16.8% | -232.1% | -94.4% |
| 3 y3 years | - | -587.6% | -178.5% |
| 5 y5 years | - | - | - |
MLTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +16.8% | -587.6% | at low | -178.5% | at low |
| 5 y | 5 years | at high | +16.8% | -587.6% | at low | -231.8% | at low |
| alltime | all time | at high | +16.8% | -587.6% | at low | -231.8% | at low |
MoonLake Immunotherapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$43.08 M(+41.0%) | -$108.45 M(+38.4%) |
| June 2024 | - | -$30.55 M(+54.3%) | -$78.35 M(+28.5%) |
| Mar 2024 | - | -$19.80 M(+31.8%) | -$60.98 M(+12.7%) |
| Dec 2023 | -$54.11 M | -$15.03 M(+15.8%) | -$54.11 M(-3.0%) |
| Sept 2023 | - | -$12.97 M(-1.6%) | -$55.78 M(-3.1%) |
| June 2023 | - | -$13.18 M(+2.0%) | -$57.57 M(-7.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$12.93 M(-22.6%) | -$62.04 M(-4.6%) |
| Dec 2022 | -$65.05 M | -$16.69 M(+13.0%) | -$65.05 M(+34.5%) |
| Sept 2022 | - | -$14.77 M(-16.3%) | -$48.36 M(+21.3%) |
| June 2022 | - | -$17.65 M(+10.7%) | -$39.85 M(-27.4%) |
| Mar 2022 | - | -$15.94 M(+154.4%) | -$54.89 M(+40.9%) |
| Sept 2021 | - | -$6.26 M(-80.8%) | -$38.95 M(+19.2%) |
| June 2021 | - | -$32.68 M | -$32.68 M |
FAQ
- What is MoonLake Immunotherapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics annual EBITDA year-on-year change?
- What is MoonLake Immunotherapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics quarterly EBITDA year-on-year change?
- What is MoonLake Immunotherapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics TTM EBITDA year-on-year change?
What is MoonLake Immunotherapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of MLTX is -$54.11 M
What is the all time high annual EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$54.11 M
What is MoonLake Immunotherapeutics annual EBITDA year-on-year change?
Over the past year, MLTX annual earnings before interest, taxes, depreciation & amortization has changed by +$10.94 M (+16.82%)
What is MoonLake Immunotherapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of MLTX is -$43.08 M
What is the all time high quarterly EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$6.26 M
What is MoonLake Immunotherapeutics quarterly EBITDA year-on-year change?
Over the past year, MLTX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$30.11 M (-232.06%)
What is MoonLake Immunotherapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of MLTX is -$108.45 M
What is the all time high TTM EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$32.68 M
What is MoonLake Immunotherapeutics TTM EBITDA year-on-year change?
Over the past year, MLTX TTM earnings before interest, taxes, depreciation & amortization has changed by -$52.68 M (-94.44%)